FitLife Brands, Inc.
NASDAQ•FTLF
CEO: Mr. Dayton Robert Judd CPA
Sector: Consumer Defensive
Industry: Packaged Foods
Listing Date: 2007-11-02
FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.
Contact Information
Market Cap
$148.66M
P/E (TTM)
22.0
10.8
Dividend Yield
--
52W High
$20.98
52W Low
$9.83
52W Range
Rank33Top 25.7%
4.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$23.49M+46.99%
4-Quarter Trend
EPS
$0.10-56.52%
4-Quarter Trend
FCF
$3.66M+78.99%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Jumps Post-Acquisition Quarterly revenue reached $23,485K, surging 47% compared to prior period. Nine month revenue $55,548K, up 12%.
Gross Profit Rises 25% Q3 Gross Profit totaled $8,736K, a 25% increase driven by Irwin acquisition volume and higher MusclePharm sales.
Total Assets Nearly Double Total Assets grew to $109,984K by September 30, 2025, significantly higher than $58,531K reported December 31, 2024.
Net Income Falls Sharply Q3 Net Income $921K decreased 57% versus prior year, impacted by $820K merger expense and lower gross margin.
Risk Factors
Gross Margin Pressure Continues Q3 Gross Margin dropped 6.6 points to 37.2% due to lower margin Irwin sales and $392K inventory step-up amortization.
High Acquisition Expenses Nine month Merger and Acquisition expense reached $1,848K, primarily transaction costs related to the recent Irwin acquisition.
Increased Debt Load Total Liabilities rose to $68,092K, supported by $40,625K outstanding Irwin Term Loan debt following August acquisition funding.
Goodwill Impairment Potential Stock price volatility impacts goodwill valuation; management notes potential impairment if fair value falls below carrying amount.
Outlook
Liquidity Sufficient Twelve Months Cash from operations and reserves expected to provide sufficient liquidity for the next twelve months, despite higher debt.
Finalizing Irwin Asset Valuation Company actively reviewing models for provisional goodwill and intangible assets from the August 8, 2025 Irwin acquisition.
Interest Rate Swap Executed Entered $20,000K interest rate swap to fix approximately 50% of variable rate term loan exposure until August 2030.
Rationalizing Advertising Spend Ongoing efforts focus on rationalizing advertising spend on less effective campaigns while increasing spend on core brands.
Peer Comparison
Revenue (TTM)
$1.53B
NATR$474.54M
BRCC$391.40M
Gross Margin (Latest Quarter)
LFVN81.0%
NATR73.3%
SKIN64.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NATR | $421.12M | 28.1 | 9.5% | 5.4% |
| BRCC | $305.58M | -6.9 | -54.3% | 28.3% |
| EWCZ | $224.44M | 15.6 | 15.5% | 53.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
16.1%
Strong Growth
4Q Net Income CAGR
-23.7%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Mar 26, 2026
EPS:$0.25
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 13, 2025|Revenue: $23.49M+47.0%|EPS: $0.10-56.5%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 14, 2025|Revenue: $16.13M-4.7%|EPS: $0.19-33.5%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 15, 2025|Revenue: $15.94M-3.7%|EPS: $0.22-6.3%MissForm 10-K/A - FY 2024
Period End: Dec 31, 2024|Filed: Apr 29, 2025|Revenue: $64.47M+22.3%|EPS: $0.98+65.6%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 27, 2025|Refer to amended dataForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 14, 2024|Revenue: $15.98M+14.9%|EPS: $0.23+20.6%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 14, 2024|Revenue: $16.93M+14.7%|EPS: $0.29+29.4%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 14, 2024|Revenue: $16.55M+54.1%|EPS: $0.23+1250.0%N/A